Cytrellis Biosystems is a medical technology company developing a new, proprietary class of aesthetic devices. Our devices are designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading dermatologists and plastic surgeons to develop unique product solutions which emphasize safety, clinical results and improved quality of life. We are a Massachusetts based venture capital backed company.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/05/18 | $28,500,000 | Series B |
ARCH Venture Partners Biomatics Capital Partner Fund Management The Merz Venture Initiative | undisclosed |
| 09/21/21 | $50,000,000 | Series C |
ARCH Venture Partners D1 Capital Partners  PFM Health Sciences Sands Capital | undisclosed |
